5-Aminolevulinate synthase (ALAS) is the first and ratelimiting enzyme of heme biosynthesis in humans, animals, other non-plant eukaryotes, and a-proteobacteria. It catalyzes the synthesis of 5-aminolevulinic acid, the first common precursor of all tetrapyrroles, from glycine and succinyl-coenzyme A (sCoA) in a pyridoxal 5 0 -phosphate (PLP)-dependent manner. X-linked sideroblastic anemias (XLSAs), a group of severe disorders in humans characterized by inadequate formation of heme in erythroblast mitochondria, are caused by mutations in the gene for erythroid eALAS, one of two human genes for ALAS. We present the first crystal structure of homodimeric ALAS from Rhodobacter capsulatus (ALAS Rc ) binding its cofactor PLP. We, furthermore, present structures of ALAS Rc in complex with the substrates glycine or sCoA. The sequence identity of ALAS from R. capsulatus and human eALAS is 49%. XLSA-causing mutations may thus be mapped, revealing the molecular basis of XLSA in humans. Mutations are found to obstruct substrate binding, disrupt the dimer interface, or hamper the correct folding. The structure of ALAS completes the structural analysis of enzymes in heme biosynthesis.
Introduction
Tetrapyrroles, such as hemes and chlorophylls, are arguably among the most important pigments in the biosphere and the most versatile of cofactors. They are required for molecular, energy, and electron transport, O 2 and CO 2 sensing, as well as in countless enzymatic reactions (Dailey, 1997; Frankenberg et al, 2003) .
The initial enzyme of tetrapyrrole biosynthesis, 5-aminolevulinate synthase (ALAS; EC 2.3.1.37), was discovered by Shemin (Shemin and Kikuchi, 1958) and Neuberger (Gibson et al, 1958) . ALAS catalyzes the decarboxylative condensation of glycine and succinyl-coenzyme A (sCoA) yielding 5-aminolevulinic acid (ALA), the universal precursor of all tetrapyrroles. Much later, ALAS was found to be restricted to non-plant eukaryotes and the a-group of proteobacteria (Jordan, 1990) . In plants and most bacteria, ALA is instead derived from tRNA-bound glutamate in two enzymatic steps via the C 5 pathway involving glutamyl-tRNA reductase (Hungerer et al, 1996; Moser et al, 1999 Moser et al, , 2001 ) and glutamate-1-semialdehyde-2,1-aminomutase (Hennig et al, 1997) .
Humans and other mammals produce two isoforms of ALAS: housekeeping hALAS, ubiquitously expressed in all cell types, and erythroid-specific eALAS, exclusively produced in developing erythrocytes (Riddle et al, 1989) . eALAS produces B90% of the total body heme. ALAS is highly conserved from a-proteobacteria to humans, the sequence identity ranging from 40 to 80%. Thus, for example, the sequence identity of human eALAS and Rhodobacter capsulatus ALAS (ALAS Rc ) is 49%, rising to 70% if similar residues are included.
ALAS is a pyridoxal 5 0 -phosphate (PLP)-dependent homodimer, composed of 44-65 kDa monomers. It belongs to the oxoamine synthase subgroup of a-division PLP-dependent enzymes (Mehta and Christen, 1994; Christen and Mehta, 2001) . The catalytic mechanism of the ALAS reaction involves binding of glycine to PLP to form a PLP-glycine complex (external aldimine; Scheme 1). Following proton abstraction, the resonance-stabilized quinonoid intermediate nucleophilically attacks sCoA, the second substrate. Release of CoA and decarboxylation of the resulting intermediate yields ALA. The final step, release of ALA, is the slowest and hence rate-limiting step of the reaction (Ferreira et al, 1993; Zhang and Ferreira, 2002; Cheltsov et al, 2003) .
Mutations in the human gene for eALAS (ALAS2) cause X-linked sideroblastic anemia (XLSA), a group of severe disorders characterized by inadequate formation of heme and accumulation of iron in erythroblast mitochondria (May and Bishop, 1998) . The physiological concentration of iron is normally tightly regulated to prevent nonspecific iron binding (Andrews, 1999) . Iron overloads, as in XLSA, disturb the cellular reduction-oxidation state and reduce cellular lifetime, making eALAS critical for erythroid cell differentiation and survival (Harigae et al, 2003) . A biological half-life of a mere hour means that mammalian eALAS is notoriously difficult to purify from natural sources (Furuyama and Sassa, 2002) . We have therefore selected bacterial ALAS for the structural elucidation, especially as the high degree of sequence identity between bacterial and the core human ALAS should allow the former to serve as a suitable structural model for the latter.
Here we describe the first crystal structure of full-length ALAS from R. capsulatus (ALAS Rc ), including the cofactor PLP, at 2.1 Å resolution. In addition, we present the structures of ALAS Rc , respectively, binding glycine and sCoA at 2.7 and 2.8 Å . The high degree of conservation between ALAS Rc and human eALAS allows us to derive a model for the core of human eALAS, elucidating the structural and functional implications of naturally occurring XLSA-inducing mutations. In addition, we can now elucidate the structural aspects of catalysis of the oxoamine synthase subfamily of PLPdependent enzymes in unprecedented detail.
Results and discussion
The structure of ALAS ALAS has previously been identified as a member of the oxoamine synthase subgroup of a-division PLP-dependent enzymes (Grishin et al, 1995; Mehta and Christen, 2000; Schneider et al, 2000) . The structure of ALAS from R. capsulatus (ALAS Rc ) was correspondingly solved by molecular replacement, using a model consisting of the superimposed structures of 8-amino-7-oxononanoate synthase (AONS; PDB code 1BS0; Alexeev et al, 1998) and 2-amino-3-ketobutyrate CoA ligase (KBL; PDB code 1FC4; Schmidt et al, 2001 ) of this subgroup. The structure was analyzed to a maximum resolution of 2.1 Å , with two dimers in the asymmetric unit. Data collection and refinement statistics are summarized in Table I. ALAS Rc is a tightly interlocked homodimer (Figure 1 ). Each monomer consists of three domains, all of which participate in dimerization: an N-terminal domain (residues 1-52, yellow in Figure 1 ), a central, catalytic domain (residues 53-296, orange) that contributes most of the dimer interface, and a C-terminal domain (residues 297-401, red). The N-terminal domain consists of an a-helix, remote from the rest of the monomer, and a three-stranded, antiparallel b-sheet. The large central or catalytic domain bears a seven-stranded, largely parallel b-sheet (b-strand order: 324567 0 1, 0 implying an antiparallel orientation) covered on either side by nine a-helices in repeated b/a motifs. The C-terminal domain includes a three-stranded antiparallel b-sheet contacting both N-terminal and catalytic domains of the same monomer and three a-helices contacting the N-terminal domain.
PLP-binding site and active site pocket
An ALAS Rc dimer symmetrically binds two PLP molecules (green in Figure 1 ). In the absence of substrate or product, PLP is covalently bound as a Schiff base to Lys248 (Hunter and Ferreira, 1999a) . This lysine, conserved in all ALAS, is located in loop b9-b10 of the catalytic domain. The catalytic domain of the second monomer participates in PLP binding by providing three of six hydrogen bonds to the phosphate group: Ser277*-O g and Thr278*-O g and -N (where * denotes the second monomer), in addition to (Figures 2 and 3A) . Recognition of the pyridinium ring of PLP, by contrast, exclusively involves one monomer: Val216 and His142 stack on either side of Scheme 1 The reaction mechanism of ALAS. In the substrate-free state, the cofactor PLP is bound by Lys248 (ALAS Rc ), the internal aldimine. Incoming glycine induces transaldimination, leading to PLP binding glycine rather than Lys248 (external aldimine). The substrate sCoA is nucleophilically attacked by the PLP-activated glycine, leading to the addition of succinic acid to glycine and concomitant loss of CoA. Decarboxylation (carboxylate of the glycine moiety) of this intermediate yields the PLP-bound product, released in the rate-limiting step of the reaction. the pyridinium ring, stabilizing it through hydrophobic interactions. Specificity is achieved through the hydrogen bond His217-N e2 -PLP-O3 and the salt bridge Asp214-O d2 -PLP-N d2 (the protonated nitrogen of the pyridinium ring). The latter interaction, found in most PLP-dependent enzymes, increases the electron-withdrawing potential of the pyridinium ring (Hunter and Ferreira, 1999b) . The tight binding allows PLP to remain bound during catalysis, despite losing its covalent bond to Lys248. PLP, instead, binds the substrate glycine through a Schiff base bond.
Alongside each PLP, both catalytic domains and the C-terminal domain of the PLP-binding monomer delimit the substrate-binding pocket. This pocket is connected to the enzyme surface by a channel ( Figure 4B ) created by the same domains involved in forming the active site. This channel is clearly involved in sCoA binding (see below).
Binding of substrates glycine and sCoA
To elucidate the binding mode of both substrates, we soaked crystals of ALAS Rc /PLP with either glycine or sCoA for 24 h. The resulting complexes were analyzed crystallographically to maximum resolutions of 2.7 and 2.8 Å , respectively. Unit cell parameters and space group essentially remained unchanged (Table I) , allowing glycine and sCoA to be located by difference Fourier techniques, following rigid-body and simulated-annealing refinement using the ALAS Rc /PLP structure.
The difference map of glycine-soaked crystals reveals unambiguous residual electron density alongside PLP in all four monomers in the asymmetric unit ( Figure 3B ). Glycine is thus covalently bound to PLP through a Schiff base bond, forming the so-called 'external aldimine'. The occupancy of glycine, however, appears to vary, underlining the dynamic nature of the Schiff base and the known fact that the Figure 1 The structure of the ALAS homodimer from R. capsulatus (ALAS Rc ) in ribbon representation. The N-terminal domain is rendered in yellow, the catalytic domain in orange, and the C-terminal domain in red. The cofactor PLP (green) is depicted in ball-and-stick representation, carbon in green, oxygen in red, nitrogen in blue, and phosphorus in magenta. This figure and most others were produced using PYMOL (DeLano, 2002) . dissociation constant of ALAS for glycine is surprisingly high at 1.8-30 mM (Bolt et al, 1999) . The glycine a-carboxylate group forms a weak salt bridge (3.8 Å ) with the guanidinium side chain of Arg374 (confirming its involvement; Tan et al, 1998) , and hydrogen bonds to Ser189-O g and Asn54-N d2 . In sCoA-soaked crystals, significant difference electron density is seen near the entrance of the active-site channel. In particular, the 3 0 -phosphate ADP moiety of sCoA is well defined ( Figures 3D and E) -the first time sCoA and hence its binding pocket have been located in any member of the oxoamine synthase subfamily of PLP-dependent enzymes. It is bound within a hydrophobic pocket on the surface of the enzyme. Residues Ile146 and Ile158 lie on either side of the adenine moiety, while Ile149 delimits the bottom of the pocket (Figures 2, 3D and E). Specificity is achieved through hydrogen bonds Ser139-O-N6, Asp138-O-N6, and Ser137-O g -N1, where N1 and N6 belong to the sCoA adenine moiety. The ribose moiety of sCoA, in turn, is recognized by a hydrogen bond from Lys156-N z to O3
0 . The binding pocket is located immediately alongside the entrance to the active-site channel ( Figure 4B ). At the end of the active-site channel, a planar, three-pronged electron density opposite the guanidinium group of Arg21 is visible ( Figure 3E ). We have interpreted this to mark the position of the succinate carboxylate group of sCoA, forming a salt bridge to Arg21-N Z2 . This carboxylate oxygen also forms hydrogen bonds to Thr365-O g and Asn85*-N d , while the second oxygen forms hydrogen bonds to Thr83*-O g and a buried water molecule ( Figure 2 ). Lateral van der Waals interactions with Ile86* further serve to stabilize this interaction. The carboxylate group is also seen in the absence of sCoA-indicating the high affinity for acidic groups. Only weak electron density is visible for the intermediate region better modeled as discrete water molecules. The succinyl-pantetheine moiety of sCoA is thus disordered in the absence of the second substrate glycine. Nevertheless, the positions of the 3 0 -phosphate ADP and carboxylate moieties allow the entire sCoA to be modeled into the active site tunnel in an elongated conformation ( Figure 3E and dashed black lines in Figure 2 ). The modeled positions of hydrophilic atoms of sCoA (OP1, NP1, OS1) Figure 2 Schematic representation of the active site. Glycine-bound PLP and sCoA are highlighted by bonds in black; bonds of surrounding residues are shown in dark orange. Dotted lines indicate hydrogen bonds (green numbers) and salt bridges (red) between substrates or cofactors and ALAS; green semicircles indicate hydrophobic interactions. An asterisk marks residues from the second monomer. Lys248, involved in PLP binding and catalysis, is marked by a blue box, residues affected by mutations in human eALAS by a red box. In three of four monomers of the sCoA/ALAS complex, PLP is not covalently bound to Lys248. This is documented by positive difference electron density in the absence of PLP and side chain of Lys248 (green, contoured at 3s), the negative difference density in 'enforced' Schiff-base bond (red, contoured at À3s, structure in narrow bonds), and the refined electron density of unbound PLP (blue, contoured at 1s, thick bonds). (D) The adenine and ribose moieties of sCoA bind in a hydrophobic (white) pocket with positively charged rim (blue) adjacent to the active-site channel. (E) The electron density is well defined for the 3 0 -phosphate ADP moiety and for the carboxylate group of sCoA, indicating that the central portion is not rigidly bound in the absence of the second substrate glycine. roughly correspond to the water molecules in the channel, indicating that these atoms would be stabilized by hydrogen bonds to the surrounding protein, while the remaining aliphatic parts are stabilized by hydrophobic van der Waals interactions.
In the substrate-free structure of ALAS, PLP is covalently bound by Lys248. The substrate glycine replaces Lys248 in binding to PLP, as expected (Figures 3B). However, though sCoA does not bind to PLP itself, PLP appears no longer to be bound to Lys248 in at least three (of four) monomers of this complex ( Figure 3C ). Instead, the pyridinium ring of PLP is tipped by B151 around the C5-C5A bond, so that its O3 and C4A atoms move away from Lys248-comparable to the glycine-bound state and to other external aldimines of PLP-dependent enzymes. The rotation of the PLP ring is accompanied by a movement of His142 in all substrate-bound monomers, such that it remains stacked above the PLP ring. Lys248 forms a new hydrogen bond through its N z to N g2 of the conserved residue Asn54.
Superimposing the glycine-and sCoA-bound complexes of ALAS Rc indicates that both substrates can simultaneously be accommodated within the active site, without incurring steric clashes ( Figure 4B ). Overall, this leads to an arrangement in which the distance between the glycine C a atom and CS1 of sCoA is B2.8 Å . The nucleophilic attack of CS1 by the deprotonated C a of the quinonoid, anionic glycyl-PLP to create the new C-C bond is thus feasible.
Glycine-rich stretch
A glycine-rich stretch comprising residues 77-GAGSGGTR NISGT-89, in loop a3-a4 of the catalytic domain, was earlier proposed to be involved in substrate binding (Gong et al, 1996) . Especially three residues, Gly77, Gly79, and Arg84, were found to be intolerant of mutational replacement. Indeed, the structure indicates that this loop is crucial for the recognition of the succinyl-moiety of sCoA. In particular, residues Thr83, Asn85, and Ile86 are directly involved in positioning the terminal carboxylate group of sCoA ( Figure 3E ). Structurally, this intricately folded loop is furthermore surrounded by the catalytic domain of the same monomer and all three domains of the second monomer. It therefore occupies a particularly sensitive position that may easily be disrupted by any change in the amino-acid sequence. Arg84 forms a salt bridge to Glu97, helping to stabilize the loop. Gly77 adopts a conformation reserved for glycines. Mutated to any other residue, it would be forced into a different region of the Ramachandran plot, again disrupting this loop and upsetting the recognition of succinyl.
Open and closed ALAS conformations
The crystal packing in the complex ALAS Rc /PLP places two ALAS dimers (or four monomers) into the asymmetric unit. Three of these monomers, A, D, and E, are structurally essentially indistinguishable. Monomer B, by contrast, adopts an 'open' conformation in which two loops (residues 332-348 between b11 and a14 and residues 358-374 between a14 and b12; red in Figure 4A ) of the C-terminal domain move outwards, widening the active site, the active-site channel, and opening a second channel, both longer and narrower than the first ( Figure 4C ). Comparing the 'open' and 'closed' states of ALAS indicates that in particular Thr365, located at the outermost tip of the loop 358-375, moves inwards by 3.5 Å during this transition. In the closed conformation, Thr365 is firmly positioned among the residues of the active site stabilized by a hydrogen bond Thr365-O g1 -Arg21-N Z2 and by van der Waals interactions Thr365-C g2 -Ile361-C g1 and -Met190-C e . As a result, the narrow active-site channel winds past Thr365, ending opposite the side chain of Arg21. The carboxylate group of the substrate sCoA presumably fills this end of the channel, forming a hydrogen bond to Thr365-O g (see above). Thr365 is thus crucial in locking the succinyl group into position and is itself locked into the closed position when the substrate is present.
The open conformation is observed only in one monomer of the substrate-free crystal structure. In glycine-and sCoAbound complexes, all monomers adopt the closed conformation. The open state presumably provides more facile access to the active site, especially for the extensive sCoA. The closed conformation in turn constricts the active site and active-site channel, clasping the pantetheine and succinate moieties of sCoA into position-presumably as a prelude to catalysis. An additional salt bridge Arg368-Glu17 further stabilizes the closed conformation. Arg368 is conserved in comparison with human eALAS, while Glu17 of ALAS Rc is replaced by aspartate (Asp159) in eALAS ( Figure 5A ).
Structural aspects of enzymatic reaction
Structurally and functionally, ALAS belongs to the a-division of PLP-dependent enzymes and along with AONS, serine palmitoyl transferase, and KBL constitutes the a-oxoamine synthase subfamily. These enzymes catalyze the decarboxylative condensation of a carboxylic acid CoA thioester and an amino acid (Mehta and Christen, 2000) . Of the two substrate molecules, the amino acid (glycine in ALAS) is covalently bound through a Schiff base, while CoA is bound noncovalently.
The crystal structure of ALAS Rc indicates that the PLP-glycine intermediate forms a weak salt bridge (3.8 Å ) to the conserved Arg374 ( Figure 3B ). Replacing the arginine by lysine in murine eALAS reduces its enzymatic activity, but only by 23% (Tan et al, 1998) . Clearly, a positively charged residue is required at this position, presumably to aid initial recognition and orientation of glycine prior to PLP binding. Formation of the Schiff bond in the external aldimine (Scheme 1) would cause glycine to move towards PLP and away from Arg374, weakening the salt bridge interaction. Though overall stability of the glycine would be sacrificed, a weaker salt bridge may favor elimination of the a-carboxylate as CO 2 later in the reaction.
The side-chain methyl group of Thr83* and the C a atom of PLP-glycine intermediate are in direct van der Waals contact (3.9 Å ) with each other. Amino acids other than glycine could theoretically bind only if their side chains face away from Thr83*. This would, however, block the binding site of sCoA, indicating that Thr83* is pivotal in governing the specificity of ALAS for glycine. In AONS Thr83* is replaced by a serine (Alexeev et al, 1998) , which lacks the terminal methyl group. Alanine, larger by exactly this methyl group, is hence the favored substrate of AONS. Accordingly, ALAS may be modified to accept threonine (and to a lesser extent serine, alanine and glycine) by engineering the replacement of Thr83 by serine, as shown for ALAS from R. sphaeroides (Shoolingin -Jordan et al, 2003) .
The sCoA carboxylate group is recognized by Arg21 at the far end of the substrate channel. Another two hydrogen bonds from Asn85* and Thr365 add to this recognition. A mutation of Thr365 (Thr508 in human eALAS) to serine induces XLSA (see below), confirming its crucial participation in substrate binding.
We observe that sCoA binds in the absence of glycine, indicating that binding is initiated by 3 0 -phosphate adenosine recognition. Only upon glycine binding would the succinylpantetheine 'tail', however, fill the remaining channel. The conformational equilibrium would then presumably be tipped towards the closed conformation, constricting the active-site tunnel and eliminating any excess water molecules, initiating the enzymatic reaction.
In vitro activity assays with several acyl-CoA derivatives indicate the importance of the acyl chain length and hydrophilicity (Shoolingin-Jordan et al, 1997). The crystal structure underscores these conclusions, as the optimal chain length is clearly dictated by the successful positioning of CS1 opposite glycine-C a following succinyl carboxylate recognition at the far end of the channel. This also explains why increasing the acyl-group hydrophilicity by substituting the carboxylate by carbonyl, hydroxyl, or methyl groups should negatively influence enzymatic activity. Tight binding of the succinyl carboxylate group furthermore slows the release of ALA, making it the rate-limiting step in the ALAS-catalyzed reaction (Hunter and Ferreira, 1999b) .
Modeling human eALAS on ALAS from R. capsulatus
Before the present crystal structure of ALAS from R. capsulatus, structural information on ALAS was available only for the 49 amino-acid presequence of murine ALAS from an NMR study (Goodfellow et al, 2001) , and by modeling the catalytic domain of ALAS on related enzymes such as AONS (Cheltsov et al, 2003; Shoolingin-Jordan et al, 2003) .
Excluding the variable N-terminal regulatory and targeting domain (140 residues; Conboy et al, 1992) , the catalytic core of human eALAS is 49% identical (70% similar) by sequence to ALAS Rc ( Figure 5A ). This is a particularly high degree of conservation between a human and bacterial protein, and is significantly higher than the 29% between AONS and ALAS Rc . The sequence similarity is uniformly distributed throughout the length of 401 residues. It is, however, particularly pronounced in the active site, the active-site channel, the monomer-monomer interface, and the protein core ( Figure 5A ). Compared to ALAS Rc , human eALAS bears two single-residue insertions and a single deletion in the first 40 residues of ALAS Rc , in the least-conserved part of the sequence. The high degree of amino-acid conservation and the fact that the enzymatic activity of truncated human eALAS (K M 2.6 mM glycine) is similar to that of ALAS Rc (2.8 mM), as well as ALAS from R. sphaeroides (5.8 mM), indicate that the structure of ALAS Rc represents a valid model for human eALAS.
Mutations of eALAS cause XLSA
Hereditary sideroblastic anemia or XLSA is caused by point mutations in ALAS2. In total, 42 such substitutions affecting 37 residues of human eALAS have been identified (Table II; reviewed by Bottomley, 2004) . Some of these cases have been successfully treated by supplemental pyridoxine (vitamin B 6 , converted to PLP on uptake), phlebotomy (bleeding), or ironchelating drugs. The success of treatment, however, varies especially due to the differential responsiveness of mutated eALAS patients to pyridoxine. The fact that many of the XLSA-sensitive residues of eALAS are either strictly conserved in ALAS Rc or replaced by similar residues (Table II, columns 1 and 2) now permits the precise location of these mutation sites to be mapped and analyzed ( Figure 5B ).
In our discussion of the mutations, we have assigned four groups of XLSA mutations depending on their proximity to the active site.
XLSA mutations directly involved in substrate or PLP binding (magenta in Figure 5A and B and Table II) R517C: Arg517 (Arg374 in ALAS Rc ) engages the substrate glycine carboxylate group in a salt bridge, and is thus crucial for substrate recognition and discrimination (see above; Tan et al, 1998) . Replacing arginine by shorter, uncharged cysteine would severely reduce the substrate specificity. This effect cannot be corrected by higher concentrations of PLP, hence confirming the observation that individuals carrying this mutation do not respond to pyridoxine therapy.
T388S: Thr388 (Thr245) is part of the PLP recognition pattern by hydrogen bonding the PLP phosphate. Replacing threonine by serine allows for higher rotational freedom of serine, significantly reducing the affinity of eALAS for PLP. A lower affinity for PLP may be offset by increasing its concentration. Correspondingly, patients respond favorably to pyridoxine treatment.
T508S: Thr508 (Thr365) is central to the function of ALAS. It appears essential both for active-site closure (see above) and in stabilizing sCoA. This stabilization involves hydrophobic interactions to the succinyl-moiety and a hydrogen bond to the succinyl-carboxylate group. Removing the methyl group by replacing threonine by serine would impair the balance of interactions in the active site. In particular, conformational constraint on the succinyl-moiety of sCoA would be lost, affecting the position of atom CS1 of sCoA, the atom that attacks the deprotonated C a of the PLP-glycine aldimine. The lower affinity for sCoA cannot be counteracted by an increase in the amount of PLP. Correspondingly, this mutation is not convincingly pyridoxine responsive in patients.
K299Q: Lys299 (Lys156), located on the surface of ALAS, binds the O3 0 atom of sCoA (ribose moiety) through a hydrogen bond. Replacing lysine by glutamine causes this interaction to be lost, decreasing the binding affinity of eALAS for sCoA. Patients with this mutation are reported to respond to pyridoxine treatment (Table II) . However, as PLP binding in ALAS is not affected by the mutation, the effect of pyridoxine supplementation may be indirect.
Y506 frame shift and R204 stop: Two mutations cause the polypeptide to be terminated prematurely. Termination at position 204 (61) removes the major part of the catalytic domain, while a frame shift after position 506 (363) leads, at the very least, to the loss of Arg517 (Arg374), required for glycine binding. Both polypeptides will thus not give rise to a functional enzyme, and increasing the concentration of PLP will not rescue their activity. Figure 5A and B and Table II ). The following XLSA mutations involve residues not directly in contact with the substrates glycine and sCoA, nor with PLP. They are, however, located within the core of the ALAS monomer, frequently in the immediate structural vicinity of the active site. Replacing them with physically incompatible residues upsets the active site or the binding affinity of cofactor or substrates.
XLSA mutations indirectly affecting cofactor or ligand binding (orange in
F165L: Phe165 (Phe23) structurally stabilizes the neighboring Arg163 (Arg21, Figure 2) , required for sCoA carboxylate group recognition, through hydrophobic interactions. Replacing Phe165 by leucine destabilizes Arg163, reducing the specificity of sCoA binding. As PLP binding is not affected by the mutation, response to pyridoxine treatment is marginal.
C276W: Cys276 (Leu133) is located at the N-terminal end of b-strand b5 (Figure 5A ), filling a small hydrophobic pocket. It is physically linked to residues Ser280 (Ser137) and Asp281 (Asp138) involved in recognition of the sCoA adenine moiety. Replacing this residue with the much bulkier tryptophan will severely reduce sCoA binding. As PLP binding is not affected, patients are not responsive to pyridoxine supplementation.
G291S: Gly291 (Gly148) is intermediate to Ile289 (Ile146) and Ile292 (Ile149), both part of the sCoA adenine-binding pocket. Replacing glycine by serine will upset the pocket, decreasing the affinity for sCoA. Furthermore, Gly291 is one helical turn away from His285 (His142) involved in PLP binding (Figure 2 ). Disruption of a-helix a5 will thus affect PLP binding as well. As a result, this mutation may be counteracted by increasing levels of PLP.
C395Y: Cys395 (Val252) is spatially immediately adjacent to Leu389 (Leu246), which in turn is located sequentially between Thr388 (Thr245) and Lys391 (Lys248), respectively, involved in PLP-phosphate binding and in catalysis. Replacing Cys395 by significantly larger tyrosine will adversely affect PLP binding. Correspondingly, the activity of this mutant enzyme may be rescued by higher concentrations of PLP.
G398D: Gly398 (Gly255) is wedged in between Cys258 (A115) and Thr388 (Th245), itself involved in an XLSA Residues constitute a positively charged cluster on the surface of eALAS remote from active site; potentially involved in binding sCoA synthetase (Furuyama and Sassa, 2000) I476N mutation and involved in PLP-phosphate binding. Adding a side chain by mutation to aspartate will sterically disrupt this pocket. By additionally introducing a negative charge, the negative phosphate will no longer bind. Correspondingly, pyridoxine treatment is ineffectual in this case.
I476N:
The side chain of Ile476 (Val333) stabilizes that of His360 (His217), involved in PLP binding, and Arg517 (Arg374), required for glycine recognition. Replacing this residue by asparagine will thus likely affect both PLP and glycine binding. Patients with this mutation therefore respond well to pyridoxine.
Y199H: Like Ile476 (Val333), above, Tyr199 (Tyr56) stabilizes His360 and Arg517, as well as the catalytic Lys391 (Lys248) and Asn197 (Asn54), involved in glycine binding. Replacing tyrosine by histidine, though frequently a tolerable mutation, appears to destabilize PLP and glycine binding sufficiently, so that elevated intracellular levels of PLP only partially offset the mutation.
R227C: Arg227 (Arg84), located in the glycine-rich stretch and immediately adjacent to Thr226 (Thr83), itself involved in substrate glycine and sCoA carboxylate binding, is stabilized by a buried salt bridge to Glu240 (Glu97). Replacing Arg227 by cysteine abrogates this ionic interaction. Apparently, this destabilizes the active site to such an extent that PLP supplementation proves ineffectual.
G416D: Gly416 (Gly273) is one a-helical turn removed and thus physically adjacent to Phe419 (Phe276), which is crucial for interaction with the pantetheine moiety of CoA. Gly416 is also physically close to Thr420 (Ser277) and Thr421 (Thr278), both of which bind the PLP-phosphate. Substitution of Gly416 by aspartate would hence disrupt both PLP and sCoA binding. Surprisingly, the disruption is not severe, as PLP does impart a moderate improvement in ALAS activity.
Buried XLSA mutations physically distant from the active site (green in Figure 5A and B and Table II) . Five mutational sites (accounting for eight described mutations) are quite distant with respect to the active site-, cofactor-, and substratebinding pockets. Here, the influence of a substitution is less direct. Instead, a local change may radiate throughout the structure, influencing protein stability, substrate-binding affinity, or enzymatic catalysis. Buried residues are particularly sensitive in this regard, normally permitting only conservative substitutions if complete destabilization and hence inactivation is to be prevented.
Due to the large number of mutations, the indirect effect of the mutations, and hence the partly speculative nature of the structural explanation, the discussion of these mutations is provided in the Supplementary data.
XLSA mutations on the protein surface (highlighted in blue in Figure 5A and B and Table II) . In all, 16 mutations affect the 12 separate surface-exposed residues in ALAS not located near the active-site channel. These residues are exposed to the surrounding aqueous medium and thus tend to be hydrophilic. Replacing them with hydrophobic residues or by a residue of opposite charge will generally not directly affect the binding of substrates or of cofactors. Instead, they may lead to protein destabilization and/or aggregation, affecting the amount of protein available to produce ALA. Alternatively, surface-exposed residues may affect the interaction of ALAS with other proteins. ALAS has, for example, previously been reported to bind the b-subunit of ATPspecific sCoA synthetase, the enzyme that generates sCoA for eALAS (Furuyama and Sassa, 2000) . The replacement of Asp190 by valine, an XLSA-inducing mutant (Table II) , was shown to prevent this interaction. At least six further mutations, affecting four positively charged amino acids (R436W, R448Q, R452C/H/S, R458H), cluster near Asp190, indicating that they, too, may induce XLSA by inhibiting the interaction of eALAS with sCoA synthatase.
The detailed discussion of each individual mutation is provided as Supplementary data to this publication.
Conclusions
The structure of ALAS from R. capsulatus is the first structure of this essential enzyme from tetrapyrrole biosynthesis. Coincidentally thus, the first enzyme required for heme biosynthesis in humans, animals, and a-proteobacteria is the last to be elucidated structurally. The high degree of conservation of this enzyme from bacteria to humans underlines the importance of this enzyme, the low evolutionary tolerance of changes, and allows a surprisingly detailed view of human eALAS. This will aid the understanding of the disease and allow the efficacy of pyridoxine treatment to be rationalized. It may furthermore allow sufferers of the disease and medical personnel involved in its treatment to lift the veil of uncertainty by providing firm structural evidence to understand the physical basis for the symptoms.
Materials and methods
Cloning, production, and purification of ALAS from R. capsulatus, activity assay The hemA gene of R. capsulatus (DSM 1710) was amplified from genomic DNA using PCR and cloned into the BamHI/HindIII sites of the Escherichia coli expression vector pQE30 (Qiagen). The protein was produced in E. coli M15 (pRep4) (Qiagen) cells at 201C in TB medium after induction with 0.1 mM isopropylthio-b-D-galactoside. Cells were harvested by centrifugation, disrupted by French press, and the insoluble membrane and cell wall fraction were discarded following centrifugation. ALAS Rc was isolated from the soluble fraction by Ni-NTA affinity chromatography (Ni-NTA Agarose, Qiagen), followed by anion exchange chromatography (MonoQ, Amersham Biosciences) and gel filtration (Superdex 200, Amersham Biosciences). The purified protein was concentrated to 10 mg/ ml. Protein integrity and purity were verified using SDS-PAGE, N-terminal sequencing, dynamic light scattering, and mass-spectrometric analysis.
The human ALAS2 gene encoding eALAS was amplified by PCR to yield a truncated (135 amino acids N-terminal and 34 amino acids at the C-terminus) and N-terminally His-tagged protein.
Expression and purification procedures were as described for the ALAS Rc .
Enzymatic activity was analyzed by spectrophotometrically monitoring the increase of NADH (l ¼ 340 nm) produced by a-ketoglutarate dehydrogenase during the regeneration of sCoA consumed by ALAS (Hunter and Ferreira, 1995) .
Crystallization ALAS Rc was crystallized by hanging drop vapor diffusion at 201C under anaerobic conditions (MACS1000 anaerobic workbench, Don Whitley Scientific). In all, 2 ml of protein in 20 mM Hepes, pH 7.3, 200 mM NaCl, 1 mM DTT, and 1 mM PLP was added to 2 ml of reservoir solution containing 100 mM Hepes, pH 7.5, 200 mM Na acetate, 8% isopropanol (v/v), and 20% PEG 4000. Rectangular crystals grew to a size of 50 Â 50 Â 50 mm 3 within 2 weeks. The crystals belong to space group P2 1 2 1 2 1 with cell constants a ¼ 67.3 Å , b ¼ 90.6 Å , and c ¼ 245.6 Å . A Matthews coefficient of 2.24 Å 3 /Da indicated the presence of two ALAS dimers per asymmetric unit, corresponding to a solvent content of 44% (Matthews, 1968) . For the substrate-bound structures, glycine or sCoA sodium salt was added to the reservoir solution (final concentration 10 mM) and the crystals were transferred into 4 ml of this solution and soaked for 24 h.
Data collection and structure determination X-ray diffraction data of substrate-free and substrate-soaked crystals were, respectively, collected at the beamline BW6 (DESY, Hamburg) and beamline BL1 (BESSY II, Berlin). Data were processed and scaled using the HKL suite (Otwinowski and Minor, 1997) . All further steps were performed using programs of the CCP4 suite (CCP4, 1994). The superimposed structures of AONS (PDB code 1BS0; Alexeev et al, 1998) and KBL (PDB code 1FC4; Schmidt et al, 2001) were used as a model for molecular replacement in EPMR (Kissinger et al, 1999) . CNS (Brunger et al, 1998) was used for the rigid-body and simulated-annealing refinement of all three structures. REFMAC5 was used for subsequent refinement, including NCS-restraint and TLS-refinement protocols (Murshudov et al, 1997) . The program O was used for manual model building and structural analysis (Jones et al, 1991) . Structures were validated using PROCHECK (Laskowski et al, 1993) and WHAT IF (Vriend, 1990) . Molecular depictions were prepared using PyMOL (DeLano, 2002) . Sequence alignments were performed with ClustalW (Thompson et al, 1994) , structure-based sequence alignments using DALI (Holm and Sander, 1996) .
Accession number
The coordinates of the structures have been deposited in the Protein Data Bank (Code 2BWN, 2BWO and 2BWP).
Supplementary data
Supplementary data are available at The EMBO Journal Online.
